NU-001

NU-001 is a **preclinical RNA interference therapeutic candidate** being developed by NUAgo Therapeutics for **ovarian cancer**, particularly in the context of treatment-resistant disease. Publicly available sponsor materials describe it as part of NUAgo's short RNA platform, in which **single-construct short RNAs** are delivered using a **lipo-polyplex nanoparticle** and are intended to kill tumor cells by targeting networks of survival genes through **RNAi** rather than a single disclosed molecular target. Open public sources verify the existence of the NU-001 program and its ovarian cancer focus, but they do **not** clearly disclose a specific active sequence, exact target gene set, administration route, formulation details beyond nanoparticle delivery, or a brand/INN.